Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug

Chemomab Therapeutics (CMMB) announced that data from the company’s Phase 2 SPRING trial of nebokitug in patients with primary sclerosing cholangitis, PSC, was presented in an oral session1 at BSG Live’25, the annual scientific meeting of the British Society for Gastroenterology, in Glasgow, UK. The SPRING trial data was presented by Douglas Thorburn, MD, Divisional Clinical Director for Liver and Digestive Health at the Royal Free London NHS Trust and Professor of Hepatology within the Institute for Liver and Digestive Health at UCL, and Principal Investigator of the SPRING trial. The BSG Live’25 session presented data from the double-blind, placebo-controlled portion of the SPRING trial showing that nebokitug was well-tolerated and had a safety profile comparable to placebo over 15 weeks of treatment in patients with PSC, and it demonstrated dose dependent anti-inflammatory, anti-fibrotic and anti-cholestatic effects. In a prespecified subgroup of patients with moderate to advanced disease, patients treated with nebokitug showed broad and consistent improvement in biomarkers that are associated with better clinical outcomes in PSC.